Amplia Therapeutics Limited ATX.AX Stock
Amplia Therapeutics Limited Price Chart
Amplia Therapeutics Limited ATX.AX Financial and Trading Overview
| Amplia Therapeutics Limited stock price | 0.09 AUD |
| Previous Close | 0.08 AUD |
| Open | 0.08 AUD |
| Bid | 0.08 AUD x 0 |
| Ask | 0.08 AUD x 0 |
| Day's Range | 0.08 - 0.08 AUD |
| 52 Week Range | 0.08 - 0.13 AUD |
| Volume | 87.78K AUD |
| Avg. Volume | 138.38K AUD |
| Market Cap | 15.71M AUD |
| Beta (5Y Monthly) | 0.745593 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ATX.AX Valuation Measures
| Enterprise Value | 8.93M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.211157 |
| Price/Book (mrq) | 0.98780483 |
| Enterprise Value/Revenue | 7.505 |
| Enterprise Value/EBITDA | -1.423 |
Trading Information
Amplia Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 0.745593 |
| 52-Week Change | -13.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.13 AUD |
| 52 Week Low | 0.08 AUD |
| 50-Day Moving Average | 0.09 AUD |
| 200-Day Moving Average | 0.09 AUD |
ATX.AX Share Statistics
| Avg. Volume (3 month) | 138.38K AUD |
| Avg. Daily Volume (10-Days) | 657.09K AUD |
| Shares Outstanding | 194.01M |
| Float | 111.71M |
| Short Ratio | N/A |
| % Held by Insiders | 22.09% |
| % Held by Institutions | 23.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -528.45% |
| Gross Margin | 74.14% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.20% |
| Return on Equity (ttm) | -33.13% |
Income Statement
| Revenue (ttm) | 1.19M AUD |
| Revenue Per Share (ttm) | 0.006 AUD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 979.19K AUD |
| EBITDA | -6275534 AUD |
| Net Income Avi to Common (ttm) | -6242435 AUD |
| Diluted EPS (ttm) | -0.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 9.26M AUD |
| Total Cash Per Share (mrq) | 0.05 AUD |
| Total Debt (mrq) | 2.28M AUD |
| Total Debt/Equity (mrq) | 14.37 AUD |
| Current Ratio (mrq) | 3.821 |
| Book Value Per Share (mrq) | 0.082 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -5289688 AUD |
| Levered Free Cash Flow (ttm) | -2985827 AUD |
Profile of Amplia Therapeutics Limited
| Country | Australia |
| State | VIC |
| City | Melbourne |
| Address | 350 Queen Street |
| ZIP | 3000 |
| Phone | 61 3 9123 1140 |
| Website | https://www.ampliatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Q&A For Amplia Therapeutics Limited Stock
What is a current ATX.AX stock price?
Amplia Therapeutics Limited ATX.AX stock price today per share is 0.09 AUD.
How to purchase Amplia Therapeutics Limited stock?
You can buy ATX.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amplia Therapeutics Limited?
The stock symbol or ticker of Amplia Therapeutics Limited is ATX.AX.
Which industry does the Amplia Therapeutics Limited company belong to?
The Amplia Therapeutics Limited industry is Biotechnology.
How many shares does Amplia Therapeutics Limited have in circulation?
The max supply of Amplia Therapeutics Limited shares is 194.01M.
What is Amplia Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Amplia Therapeutics Limited PE Ratio is now.
What was Amplia Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Amplia Therapeutics Limited EPS is -0.02 AUD over the trailing 12 months.
Which sector does the Amplia Therapeutics Limited company belong to?
The Amplia Therapeutics Limited sector is Healthcare.